EHRchain Partners, LLC was founded in 2018 to solve the problem of electronic health records (EHR) and transparent access for patient and provider. The company was started by OmegaPoint Partners.
Leadership
Mike Cameron Co-founder
Mike Cameron is a lifetime entrepreneur. While serving as major shareholder, President and CEO of Zephyrhills Water, he was primarily responsible for developing the once small, local company into the largest bottled water company in the Southeastern US. He negotiated the successful sale of Zephyrhills to Perrier/Nestle, making the brand a household name.
Mike is currently co-founder of the Association of Angel Investor Clubs (AAIC). AAIC creates high-growth-potential, reduced-risk companies from intellectual property developed by it technology partners, universities and government-sponsored research entities. Mr. Cameron is a graduate of Georgetown University and holds an M.B.A. from The University of Pennsylvania’s Wharton School. In addition to his business ventures, Mr. Cameron was a member of the Young Presidents Organization, served on the Board of Overseers for Georgetown University, and was the President of the Wharton School Club of Central and North Florida.
Dr. Jose E. Silva – Chief Medical Officer
Jose E. Silva, MD, MPH was born and raised in Puerto Rico. He received his undergrad degree from the prestigious Massachusetts Institute of Technology in Cambridge, Massachusetts. He then completed a Master’s degree in Public Health from the University of Puerto Rico School of Medicine. He received his medical degree from Universidad Central Del Caribe School of Medicine in Bayamon, PR. He completed his training in surgery and urology at the School of Medicine of the Medical Sciences Campus of the University of Puerto Rico, where he served as Chief Resident.
Dr. Silva has focused his training in the evaluation and surgery of enlarged prostate (BPH) and kidney stones with minimally invasive therapies such as Green Light Laser, stone laser, and lithotripsy. He is a delegate of the American Board of Urology and a member of the North American Society of Sexual Medicine. He has served as consultant in urology for insurance companies in Puerto Rico. In 2018, Dr. Silva joined the Urology Staff at Florida Hospital. He is fluent in English and Spanish.
Whit McFarlin
Mr. McFarlin is a registered professional engineer, with several patents and technical publications. From July 1993 through July 1998, McFarlin was President, CEO, and Chairman of the Board of Angeion Corporation, a public medical device company developing products in the cardiac rhythm management field (implantable defibrillators and catheter ablation systems). Mr. McFarlin led the company through its development stage into an operating company, then retired in January 1999. He continued to serve as Chairman of the Board through January 2000. From 1990 to 1993, Mr. McFarlin was Co-Founder, President, CEO, and Chairman of the Board of CLARUS Medical Systems, Inc., a private medical device company developing and manufacturing products for the orthopedic and neuro-endoscopy markets. Mr. McFarlin served on the Board of Directors of CLARUS Medical until the Company was acquired in February 2000. From 1985 to 1990, Mr. McFarlin was President and CEO of Everest and Jennings, International, Ltd., a $200 million manufacturer of durable medical equipment for the physically challenged. This Company was acquired in 1990. From 1977 to 1985, McFarlin held several positions at Medtronic, Inc., joining the company as Vice President of Research and Development for pacemakers, leads and cardiovascular instrumentation. He was later named Executive Vice President, responsible for Medtronic’s US Cardiovascular business. Medtronic is the world leader in cardiac rhythm management. From 1964 to 1977, Mr. McFarlin served in a variety of engineering management capacities at Texas A&M University, TRACOR, Inc. (Texas), and Beckman Instruments (California). In 1963, McFarlin earned a Bachelor of Science degree in Physics and Mathematics from Henderson University in Arkansas. His professional career began as Chief Engineer of Texas A&M Nuclear Particle Accelerator Program, while completing a Master of Science degree in Nuclear Engineering.
Mr. McFarlin has previously served on the Board of Directors of: Autonomous Technologies, a public laser eye surgery company (acquired by Summit Technologies), PSICOR, a public cardiovascular company (acquired by Baxter, Inc.); Zero Corporation, a public diversified electronic equipment company (merged with Applied Power, Inc.); FENA Design, Inc. a private durable medical equipment company (acquired by Dane Industries); and POSSIS Medical, a public cardiovascular company (acquired by Bayer Corporation). Mr. McFarlin has also served on the Technical Advisory Board of Med Source Technologies, Inc. (a $150 million public company serving the component manufacturing needs of the medical device industry), as well as serving as Audit Committee Chairman for several public companies and on numerous strategic and planning board committees.
Dennis McBride
Since 2010 Dr. McBride has been Founder of Intellectual Property Matters LLC (North Carolina) and a Partner at ipCapital Licensing Company LLC. Dr. McBride has 38 years of professional experience, as both an individual contributor in a wide variety of technical assignments and as a manager at various levels. He joined Lenovo (United States), Inc. in 2005 as Director of Intellectual Property Licensing as part of IBM’s divestiture of its Personal Computing Division. He was also appointed to the Lenovo Singapore Board of Directors. Dr. McBride’s thirty-one year IBM career spanned several divisions, including Research, Microelectronics, Personal Computers and Mainframe Systems. As a Program Director of Licensing he was in charge of monetizing the IP portfolio. These comprised patent infringement assertions; business development of trademark and technology licensing; identifying, negotiating and executing new deals to grow IP income; and managing the annuity income stream. Dr. McBride worked with Finance, Accounting, IP Law, and Product Development while having overall program management responsibility for IP income. He was also responsible for IP Defense in areas such as non-infringement through prior art and other defenses, working in concert with IP Law and General Legal functions. Dr. McBride drove the Patent Portfolio Management process to evaluate invention diCHNGosures, select the most valuable inventions for first country and foreign counterpart filings within budget, and evaluate patents when maintenance fees were due. Earlier career responsibilities included Research Staff Member and management roles at IBM’s T.J. Watson Research Center in Yorktown Heights, NY, technology strategy development, and hardware and software product development. He is an inventor with several patents. Dr. McBride has a Ph.D. (EE) from Polytechnic Institute of NY and M.S.(EE), B.S.(EE) degrees, combined honors curriculum, from Purdue University.
Ken Peach
Ken Peach is executive director of the Health Council of East Central Florida, the health planning organization for Brevard, Osceola, Orange, and Seminole counties. He serves on numerous local health planning boards. Ken’s career has included hospital, hospital association, physician office, and nursing home management. Additionally, he has owned and operated commercial radio stations and a health insurance agency. Ken has his undergraduate degree in Communication from Seton Hall University, and an MBA with a concentration in Health Administration from the Florida Institute of Technology. Ken and his wife Anne have resided in the Orlando area since 1983.
Dan Liptak CTO
Dan Liptak got his start early when he first discovered computers at 10 years old. An internship at NASA during high school put him on a 20-year path in Information Technology. He registered his first domain name in 1998 and has been helping companies big and small build their web presence ever since. With his experience in the computer industry along with his passion for entrepreneurism, Dan’s attitude and culture within the Collaborative Fund Partners team is well-suited.